glycine has been researched along with Hemorrhage in 46 studies
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The first clinical studies evaluating the safety and efficacy of melagatran, a novel, direct thrombin inhibitor, given subcutaneously as prophylaxis for venous thromboembolism (VTE) following total hip (THR) or total knee replacement (TKR) are reported." | 9.10 | Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. ( Ahnfelt, L; Arfwidsson, AC; Björkström, S; Elvander, CS; Eriksson, BI; Eriksson, UG; Folestad, A; Frison, L; Kälebo, P; Ogren, M; Sjöstedt, A, 2002) |
| "The antithrombotic and bleeding properties of the oral direct thrombin inhibitor ximelagatran and of warfarin were investigated in an experimental venous thrombosis and bleeding model in anaesthetized rats." | 7.73 | The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. ( Carlsson, S; Elg, M, 2005) |
| " The purpose of this study was to use a rabbit arterial thrombosis prevention and ear bleeding model to determine whether for equivalent efficacy, melagatran, a synthetic direct thrombin inhibitor, is safer than hirudin." | 7.72 | The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. ( Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI, 2003) |
| "Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b." | 6.71 | The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003) |
| "The pharmacokinetic dose linearity and reproducibility, the effects on ex-vivo coagulation time assays and bleeding time, and tolerability of the direct thrombin inhibitor melagatran following subcutaneous (s." | 5.10 | Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men. ( Eriksson, UG; Johansson, S; Larson, G; Larsson, M; Ohlsson, L; Wåhlander, K, 2003) |
| "The first clinical studies evaluating the safety and efficacy of melagatran, a novel, direct thrombin inhibitor, given subcutaneously as prophylaxis for venous thromboembolism (VTE) following total hip (THR) or total knee replacement (TKR) are reported." | 5.10 | Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. ( Ahnfelt, L; Arfwidsson, AC; Björkström, S; Elvander, CS; Eriksson, BI; Eriksson, UG; Folestad, A; Frison, L; Kälebo, P; Ogren, M; Sjöstedt, A, 2002) |
| " Herein, inspired by fibrinogen binding to activated platelets in thrombosis, this article reports a fibrinogen-mimicking, activated-platelet-sensitive nanocoacervate to enhance thrombus penetration of tissue plasminogen activator (tPA) for targeted thrombolytic therapy." | 4.12 | A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy. ( Chen, R; Guo, Y; Huang, Y; Jiang, J; Li, Y; Ren, J; Zhao, Q; Zhou, J, 2022) |
| "The antithrombotic and bleeding properties of the oral direct thrombin inhibitor ximelagatran and of warfarin were investigated in an experimental venous thrombosis and bleeding model in anaesthetized rats." | 3.73 | The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. ( Carlsson, S; Elg, M, 2005) |
| " The purpose of this study was to use a rabbit arterial thrombosis prevention and ear bleeding model to determine whether for equivalent efficacy, melagatran, a synthetic direct thrombin inhibitor, is safer than hirudin." | 3.72 | The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. ( Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI, 2003) |
| "Ximelagatran was to be initiated within the first two postoperative days." | 2.71 | Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. ( Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N, 2003) |
| "Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b." | 2.71 | The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003) |
| "Glyphosate is an organophosphorus compound and the active ingredient in commonly used herbicides, whereas polyoxyethyleneamine (POEA) is a nonionic surfactant often coupled with glyphosate in these herbicides to increase their efficacy." | 1.62 | Glyphosate and Polyoxyethyleneamine Ingestion Leading to Renal, Hepatic, and Pulmonary Failure. ( Bigner, JA; Burney, HE; Fiester, SE; Fulcher, JW; Schammel, CMG; Teuber, JM; Ward, ME; Wheeler, JF; Wheeler, SK, 2021) |
| "This glycine was located in strand 5B and was well conserved in other serpins." | 1.46 | Mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerisation. ( Iwaki, T; Kanayama, N; Nagahashi, K; Suzuki-Inoue, K; Takano, K; Umemura, K; Urano, T, 2017) |
| "When bleeding was repeated after 10 min (B2), arterial pressure dropped promptly, and plasma AVP, ANG II, osmolality and glucose augmented remarkably." | 1.33 | Anteroventral third ventricular N-methyl-D-aspartate receptors, but not metabotropic glutamate receptors are involved in hemorrhagic AVP secretion. ( Watanabe, K; Yamaguchi, K, 2005) |
| "Platelet-type von Willebrand disease (plt-VWD) is a congenital bleeding disorder characterized by gain-of-function mutations of GPIbalpha." | 1.32 | Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease. ( Ikeda, Y; Matsubara, Y; Murata, M; Sugita, K, 2003) |
| "Lung hemorrhage was seen in the animals with pancreatitis untreated with ONO-5046 24 hr following the first cerulein injection." | 1.29 | Neutrophil elastase inhibitor (ONO-5046) prevents lung hemorrhage induced by lipopolysaccharide in rat model of cerulein pancreatitis. ( Guo, L; Ikei, S; Ogawa, M; Sugita, H; Yamaguchi, Y, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (41.30) | 18.7374 |
| 1990's | 5 (10.87) | 18.2507 |
| 2000's | 15 (32.61) | 29.6817 |
| 2010's | 5 (10.87) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y | 1 |
| Jiang, J | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Zhao, Q | 1 |
| Zhou, J | 1 |
| Li, Y | 1 |
| Chen, R | 1 |
| Bigner, JA | 1 |
| Fiester, SE | 1 |
| Fulcher, JW | 1 |
| Schammel, CMG | 1 |
| Ward, ME | 1 |
| Burney, HE | 1 |
| Wheeler, JF | 1 |
| Wheeler, SK | 1 |
| Teuber, JM | 1 |
| Capmas, P | 1 |
| Levaillant, JM | 1 |
| Fernandez, H | 1 |
| Lu, Q | 1 |
| Yang, L | 1 |
| Manithody, C | 1 |
| Wang, X | 1 |
| Rezaie, AR | 1 |
| Iwaki, T | 1 |
| Nagahashi, K | 1 |
| Takano, K | 1 |
| Suzuki-Inoue, K | 1 |
| Kanayama, N | 1 |
| Umemura, K | 1 |
| Urano, T | 1 |
| Yokoyama, T | 1 |
| Tsushima, K | 1 |
| Ushiki, A | 1 |
| Kobayashi, N | 1 |
| Urushihata, K | 1 |
| Koizumi, T | 1 |
| Kubo, K | 1 |
| Sribanditmongkol, P | 1 |
| Jutavijittum, P | 1 |
| Pongraveevongsa, P | 1 |
| Wunnapuk, K | 1 |
| Durongkadech, P | 1 |
| Eriksson, BI | 3 |
| Agnelli, G | 2 |
| Cohen, AT | 2 |
| Dahl, OE | 2 |
| Mouret, P | 2 |
| Rosencher, N | 2 |
| Eskilson, C | 2 |
| Nylander, I | 1 |
| Frison, L | 2 |
| Ogren, M | 2 |
| Klement, P | 1 |
| Carlsson, S | 3 |
| Rak, J | 1 |
| Liao, P | 1 |
| Vlasin, M | 1 |
| Stafford, A | 1 |
| Johnston, M | 1 |
| Weitz, JI | 1 |
| ANTUZZI, P | 1 |
| KILPI, S | 1 |
| VIIKARI, SJ | 1 |
| JAAKKOLA, S | 1 |
| MULFORD, DJ | 1 |
| GRAY, CH | 1 |
| SCOTT, JJ | 1 |
| AOKI, K | 1 |
| MILANI, L | 1 |
| Johansson, S | 1 |
| Wåhlander, K | 1 |
| Larson, G | 1 |
| Ohlsson, L | 1 |
| Larsson, M | 1 |
| Eriksson, UG | 2 |
| Matsubara, Y | 1 |
| Murata, M | 1 |
| Sugita, K | 1 |
| Ikeda, Y | 1 |
| Lassen, MR | 1 |
| Kälebo, P | 2 |
| Panfilov, S | 1 |
| Andersson, M | 1 |
| Freij, A | 1 |
| Levi, M | 1 |
| Bijsterveld, NR | 1 |
| Keller, TT | 1 |
| Hagio, T | 2 |
| Matsumoto, S | 2 |
| Nakao, S | 2 |
| Abiru, T | 1 |
| Ohno, H | 1 |
| Kawabata, K | 3 |
| Matsuoka, S | 1 |
| Elg, M | 2 |
| Yamaguchi, K | 1 |
| Watanabe, K | 1 |
| Meyer, M | 1 |
| Dietzel, H | 1 |
| Kaetzel, R | 1 |
| Schmidt, D | 1 |
| Liebscher, K | 1 |
| Brennan, SO | 1 |
| Dubernard, JM | 1 |
| Anquetil, R | 1 |
| Brisset, JM | 1 |
| de Campos-Freire, G | 1 |
| Cukier, J | 1 |
| Gelet, A | 1 |
| Guo, L | 1 |
| Yamaguchi, Y | 1 |
| Ikei, S | 1 |
| Sugita, H | 1 |
| Ogawa, M | 1 |
| Rypins, EB | 1 |
| Milne, N | 1 |
| Sarfeh, IJ | 1 |
| Tomizawa, N | 1 |
| Ohwada, S | 1 |
| Ohya, T | 1 |
| Kawashima, Y | 1 |
| Takeyoshi, I | 1 |
| Morishita, Y | 1 |
| Imamura, M | 1 |
| Mikami, Y | 1 |
| Takahashi, H | 1 |
| Yamauchi, H | 1 |
| Gustafsson, D | 1 |
| Van Aken, H | 1 |
| Bode, C | 1 |
| Darius, H | 1 |
| Diehm, C | 1 |
| Encke, A | 1 |
| Gulba, DC | 1 |
| Haas, S | 1 |
| Hacke, W | 1 |
| Puhl, W | 1 |
| Quante, M | 1 |
| Riess, H | 1 |
| Scharf, R | 1 |
| Schellong, S | 1 |
| Schrör, T | 1 |
| Schulte, KL | 1 |
| Tebbe, U | 1 |
| Fiessinger, JN | 1 |
| Ahnfelt, L | 1 |
| Björkström, S | 1 |
| Sjöstedt, A | 1 |
| Folestad, A | 1 |
| Arfwidsson, AC | 1 |
| Elvander, CS | 1 |
| Smith, JE | 1 |
| Ruggeri, ZM | 1 |
| Mannucci, PM | 1 |
| Allain, JP | 1 |
| Frommel, D | 1 |
| Suzuki, M | 1 |
| Sugitani, M | 1 |
| Imaki, K | 1 |
| Toda, M | 1 |
| Miyamoto, T | 1 |
| Hahn, RG | 1 |
| Come, SE | 1 |
| Shohet, SB | 1 |
| Robinson, SH | 1 |
| Breckenridge, RT | 1 |
| Ratnoff, OD | 1 |
| Mazur, A | 1 |
| Peterson, CA | 1 |
| Borucki, DT | 1 |
| Austin, G | 1 |
| Desmond, J | 1 |
| Borsook, H | 1 |
| Ratner, K | 1 |
| Tattrie, B | 1 |
| Teigler, D | 1 |
| Lajtha, LG | 1 |
| Sardesai, VM | 1 |
| Park, H | 1 |
| Orten, JM | 1 |
| Nagai, K | 1 |
| Kakishita, E | 1 |
| Shanbrom, E | 1 |
| Thelin, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In-office Hysteroscopic Laser Ablation for Symptomatic Submucous Uterine Fibroids: Impact on Size and Vascularization.[NCT05604001] | 20 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for glycine and Hemorrhage
| Article | Year |
|---|---|
Surgical techniques and outcome in the management of submucous fibroids.
Topics: Embolism; Female; Fertility; Glycine; Gynecology; Hemorrhage; Humans; Hysteroscopy; Leiomyoma; Pregn | 2013 |
Recombinant factor VIIa as an antidote for anticoagulant treatment.
Topics: Anticoagulants; Azetidines; Benzylamines; Factor VII; Factor VIIa; Glycine; Helminth Proteins; Hemor | 2004 |
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzyla | 2001 |
[Treatment of deep vein thrombosis. Current and future questions].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Hemorrhage; Heparin, Low-Mo | 2001 |
Therapy of hereditary disorders of blood coagulation.
Topics: Abdomen, Acute; Afibrinogenemia; Blood Coagulation Disorders; Blood Transfusion; Cerebral Hemorrhage | 1968 |
5 trials available for glycine and Hemorrhage
| Article | Year |
|---|---|
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2003 |
Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
Topics: Adult; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Biological Availability; Blood Co | 2003 |
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2003 |
Analysis of nutrient hepatic blood flow after 8-mm versus 16-mm portacaval H-grafts in a prospective randomized trial.
Topics: Aniline Compounds; Follow-Up Studies; Glycine; Hemorrhage; Hepatic Encephalopathy; Humans; Imino Aci | 1995 |
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2002 |
36 other studies available for glycine and Hemorrhage
| Article | Year |
|---|---|
A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.
Topics: Animals; Arginine; Aspartic Acid; Chitosan; Fibrinogen; Fibrinolytic Agents; Glycine; Hemorrhage; He | 2022 |
Glyphosate and Polyoxyethyleneamine Ingestion Leading to Renal, Hepatic, and Pulmonary Failure.
Topics: Acute Kidney Injury; Adult; Edema; Glycine; Glyphosate; Hemorrhage; Herbicides; Humans; Liver; Liver | 2021 |
Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.
Topics: Amino Acid Substitution; Cysteine Endopeptidases; Enzyme Activation; Enzyme Precursors; Factor IX; F | 2015 |
Mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerisation.
Topics: Aged; Amino Acid Substitution; Animals; Arginine; Chlorocebus aethiops; Conserved Sequence; COS Cell | 2017 |
Acute lung injury with alveolar hemorrhage due to a novel swine-origin influenza A (H1N1) virus.
Topics: Acute Lung Injury; Adult; Antiviral Agents; Female; Glycine; Hemorrhage; Humans; Influenza A Virus, | 2010 |
Pathological and toxicological findings in glyphosate-surfactant herbicide fatality: a case report.
Topics: Adult; Brain; Brain Edema; Chromatography, High Pressure Liquid; Esophagus; Female; Forensic Patholo | 2012 |
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Topics: Animals; Arteries; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic | 2003 |
[Clinical tests of a new synthetic oxytocin].
Topics: Female; Glycine; Hemorrhage; Humans; Obstetric Labor Complications; Oxytocin; Pregnancy | 1954 |
The effect of glycylglycine on the buffer capacity of the blood after hemorrhage; studies with rabbits.
Topics: Acid-Base Equilibrium; Animals; Blood; Buffers; Glycine; Glycylglycine; Hemorrhage; Lagomorpha; Rabb | 1954 |
Betaine and methionine on renal hemorrhagic degeneration in rats receiving 2-amino-2-methyl propanol-1.
Topics: Amino Alcohols; Animals; Betaine; Choline; Glycine; Hemorrhage; Kidney; Kidney Diseases; Methionine; | 1955 |
The effect of haemorrhage on the incorporation of [alpha-14C]Glycine into stercobilin.
Topics: Bile Pigments; Fabaceae; Glycine; Hemorrhage; Humans | 1959 |
[ON THE EFFECTS OF ALPHA-THIOLACTOYLGLYCIN NA ON LOCAL PATHOLOGICAL CHANGES INDUCED BY HEMORRHAGIC SNAKE VENOMS OF TRIMERESURUS FLAVOVIRIDIS, TRIMERESURUS ELEGANS, TRIMERESURUS OKINAVENSIS AND AGKISTRODON BLOMOHOFFII].
Topics: Agkistrodon; Animals; Crotalid Venoms; Glycine; Hemorrhage; Injections, Intramuscular; Mice; Necrosi | 1963 |
[Clinical study of a new synthetic oxytocic drug in obstetrics].
Topics: Biomedical Research; Female; Glycine; Hemorrhage; Humans; Labor, Obstetric; Obstetrics; Oxytocics; O | 1955 |
Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease.
Topics: Bleeding Time; Blood Platelets; Blood Proteins; Cell Line; Child, Preschool; Dose-Response Relations | 2003 |
Elastase inhibition reduced death associated with acid aspiration-induced lung injury in hamsters.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cricetinae; Dose-Response Relationship, Drug; Enzyme Inhibito | 2004 |
Sivelestat, a specific neutrophil elastase inhibitor, prevented phorbol myristate acetate-induced acute lung injury in conscious rabbits.
Topics: Acute Disease; Animals; Body Weight; Bronchoalveolar Lavage Fluid; Dose-Response Relationship, Drug; | 2005 |
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
Topics: Animals; Azetidines; Benzylamines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Ev | 2005 |
Anteroventral third ventricular N-methyl-D-aspartate receptors, but not metabotropic glutamate receptors are involved in hemorrhagic AVP secretion.
Topics: Analysis of Variance; Angiotensin II; Animals; Blood Glucose; Blood Pressure; Dizocilpine Maleate; D | 2005 |
Fibrinogen Leipzig II (gamma351Gly-->Ser and gamma82Ala-->Gly): hypodysfibrinogenaemia due to two independent amino acid substitutions within the same polypeptide chain.
Topics: Adult; Afibrinogenemia; Alanine; Fibrinogen; Glycine; Haplotypes; Hemorrhage; Heterozygote; Humans; | 2007 |
[Endourethral resection of prostatic adenoma].
Topics: Anti-Bacterial Agents; Drainage; Endoscopy; Glycine; Hemorrhage; Humans; Male; Prostatectomy; Prosta | 1983 |
Neutrophil elastase inhibitor (ONO-5046) prevents lung hemorrhage induced by lipopolysaccharide in rat model of cerulein pancreatitis.
Topics: Animals; Ceruletide; Disease Models, Animal; Drug Evaluation, Preclinical; Glycine; Hemorrhage; Leuk | 1995 |
The effect of neutrophil elastase inhibitor in hepatectomy with ischemia in dogs.
Topics: Alanine Transaminase; Animals; Biomarkers; Dogs; Endothelium, Vascular; Glycine; Hemorrhage; Hepatec | 1999 |
Effect of a specific synthetic inhibitor of neutrophil elastase (ONO-5046) on the course of acute hemorrhagic pancreatitis in dogs.
Topics: alpha-Macroglobulins; Amylases; Animals; Blood Pressure; Calcium; Disease Models, Animal; Dogs; Glyc | 1998 |
Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation Factors; Factor | 2001 |
Elevated erythrocyte glutathione associated with elevated substrate in high- and low-glutathione sheep.
Topics: Adenosine Triphosphate; Animals; Erythrocytes; Glutamate-Cysteine Ligase; Glutamates; Glutathione; G | 1977 |
Preliminary trial of cyclophosphamide in the management of hemophiliacs with factor VIII inhibitors.
Topics: Adolescent; Adult; Antibodies; Antibody Formation; Blood Platelets; Child; Child, Preschool; Cycloph | 1975 |
ONO-5046, a novel inhibitor of human neutrophil elastase.
Topics: Animals; Binding, Competitive; Capillary Permeability; Cricetinae; Glycine; Guinea Pigs; Hemorrhage; | 1991 |
Influence of the fluid balance on the cortisol and glucose responses to transurethral prostatic surgery.
Topics: Absorption; Aged; Anesthesia, Epidural; Blood Glucose; Blood Pressure; Central Venous Pressure; Glyc | 1989 |
Surface remodelling of reticulocytes produced in response to erythroid stress.
Topics: Animals; Blood Transfusion; Carbon Isotopes; Cell Membrane; Chromatography, Thin Layer; Erythrocytes | 1972 |
Role of the spleen in iron metabolism.
Topics: Animals; Bone Marrow; Carbon Isotopes; Cobalt; Enzymes; Erythrocytes; Erythropoietin; Glycine; Heme; | 1969 |
Pre-assayed AHF concentrate therapy for hemophilia.
Topics: Adolescent; Adult; Antibodies; Blood Transfusion; Chemical Precipitation; Child, Preschool; Cold Tem | 1968 |
Complications of transurethral prostatic surgery.
Topics: Age Factors; Aged; Burns, Electric; Cardiovascular Diseases; Glycine; Hemorrhage; Humans; Male; Midd | 1970 |
Erythropoietin and the development of erythrocytes. Effect of erythropoietin in vitro which simulates that of a massive dose in vivo.
Topics: Aging; Animals; Bone Marrow Cells; Carbon Isotopes; Cell Differentiation; Cytoplasm; Dactinomycin; E | 1968 |
A comparison of porphyrin synthesis in certain tissues from normal and anemic dogs: some observations on the in vivo control of porphyrinogenesis.
Topics: Acetates; Amino Acids; Anemia; Animals; Dogs; Erythropoietin; Glycine; Hemorrhage; Iron; Kidney; Lev | 1968 |
Destruction of immature erythrocytes measured by bilirubin excretion.
Topics: Animals; Biliary Fistula; Bilirubin; Carbon Isotopes; Erythrocytes; Erythropoiesis; Glycine; Hemorrh | 1969 |
Experimental prophylaxis of severe hemophilia with a factor VIII concentrate.
Topics: Acute Disease; Adult; Blood Pressure; Chemical Precipitation; Factor VIII; Fibrinogen; Glycine; Hemo | 1969 |